Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Boelens, Jaap Jan  [Clear All Filters]
Journal Article
Chiesa R, Boelens JJan, Duncan CN, Kuehl J-S, Sevin C, Kapoor N, Prasad VK, Lindemans CA, Jones SA, Amartino HM, et al. Variables Affecting Outcomes After Allogeneic Hematopoietic Stem Cell Transplant for Cerebral Adrenoleukodystrophy. Blood Adv. 2021.
Shah N, Boelens JJan. Umbilical cord blood: advances and opportunities. Cytotherapy. 2015;17(6):693-694.
Major-Monfried H, Hosszu K, McAvoy DP, Vallone A, Shukla N, Gillio A, Spitzer B, Kung AL, Cancio M, Curran K, et al. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2024.
Klein OR, Bonfim C, Abraham A, Ruggeri A, Purtill D, Cohen S, Wynn R, Russell A, Sharma A, Ciccocioppo R, et al. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023.
Satty AM, Klein E, Mauguen A, Kunvarjee B, Boelens JJan, Cancio M, Curran KJ, Kernan NA, Prockop SE, Scaradavou A, et al. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. Bone Marrow Transplant. 2023.
John TD, Maron G, Abraham A, Bertaina A, Bhoopalan SVelan, Bidgoli A, Bonfim C, Coleman Z, Dezern A, Li J, et al. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 2024.
Beerepoot S, Boelens JJan, Lindemans C, de Witte MA, Nierkens S, Vrancken AFJE, Van der Knaap MS, Bugiani M, Wolf NI. Progressive demyelinating polyneuropathy after hematopoietic cell transplantation in metachromatic leukodystrophy: a case series. J Neurol. 2024.
Cancio M, Lucas AGTroullio, Bierings M, Klein E, de Witte MA, Smiers FJ, Bresters D, Boelens JJan, Smetsers SE. Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia. Bone Marrow Transplant. 2023.
A Nijstad L, Nierkens S, Lindemans CA, Boelens JJan, Bierings M, A Versluys B, van der Elst KCM, Huitema ADR. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in pediatric patients. Br J Clin Pharmacol. 2021.
Orfali N, Zhang M-J, Allbee-Johnson M, Boelens JJan, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, et al. Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy. Transplant Cell Ther. 2021.
Kernan NA, Klein E, Mauguen A, Torok-Castanza J, Prockop SE, Scaradavou A, Curran K, Spitzer B, Cancio M, Ruggiero J, et al. Persistent or new cytopenias predict relapse better than routine bone marrow aspirate evaluations after hematopoietic cell transplantation for acute leukemia or myelodysplastic syndrome in children and young adult patients. Transplant Cell Ther. 2024.
Lum SHan, Orchard PJ, Lund TC, Miller WP, Boelens JJan, Wynn R. Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome. Biol Blood Marrow Transplant. 2020.
Teshima T, Boelens JJan, Matsuoka K-I. Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Cell Ther. 2023;6(2):42-48.
Beerepoot S, Heijst H, Roos B, Wamelink MMC, Boelens JJan, Lindemans CA, van Hasselt PM, Jacobs EH, Van der Knaap MS, Teunissen CE, et al. Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. Brain. 2021.
Scaradavou A, Boelens JJan. Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML. Br J Haematol. 2022.
Daukshus NP, Cirincione A, Siver M, Mathew S, Kunvarjee B, Chan A, Boelens JJan, Seo SK, Papanicolaou GA, Kernan NA. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. J Pediatric Infect Dis Soc. 2022.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SVelan, Bonfim C, Cohen S, Dezern A, Louis C, Oved J, Pavel-Dinu M, et al. International society for cell & gene therapy stem cell engineering committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023.
de Koning C, Langenhorst J, van Kesteren C, Lindemans CA, Huitema ADR, Nierkens S, Boelens JJan. Innate immune recovery predicts CD4+ T-cell reconstitution after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, Lopez-Yurda M, A Versluijs B, C Zwaan M, Lindemans CA, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111-e120.
Lakkaraja M, Mauguen A, Boulad F, Cancio MI, Curran KJ, Harris AC, Kernan NA, Klein E, Kung AL, Oved J, et al. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients. Cytotherapy. 2024.
Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJan, Mason RW, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future. Biol Blood Marrow Transplant. 2019.
Ferrua F, Galimberti S, Courteille V, Slatter MAnne, Booth C, Moshous D, Neven B, Blanche S, Laberko A, Shcherbina A, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC Study. J Allergy Clin Immunol. 2019.
Lucas AGTroullio, Boelens JJan, Prockop SE, Curran KJ, Bresters D, Kollen W, Versluys B, Bierings MB, Archer A, Davis E, et al. Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. Front Oncol. 2023;13:1221782.
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, et al. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Kunvarjee B, Bidgoli A, Madan RPellett, Vidal E, McAvoy D, Hosszu KK, Scaradavou A, Spitzer BG, Curran KJ, Cancio M, et al. Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. J Allergy Clin Immunol. 2023.

Pages